Published on
May 15, 2026
- 12:00 GMT
CB Therapeutics: After the Executive Order, Supply Becomes the Binding Constraint on Psychedelic Medicine
CARLSBAD, CA, UNITED STATES, May 15, 2026 /EINPresswire.com/ -- The April 18, 2026 U.S. Executive Order on Psychedelic Medicines committed $50 million to ibogaine research, directed the FDA to issue priority review vouchers for qualifying …
Distribution channels:
Beauty & Hair Care, Chemical Industry
...
